Biogen Inc. (ETR:IDP)
Germany
· Delayed Price · Currency is EUR | Market Cap | 17.35B |
| Revenue (ttm) | 8.51B |
| Net Income (ttm) | 1.30B |
| Shares Out | n/a |
| EPS (ttm) | 8.90 |
| PE Ratio | 13.32 |
| Forward PE | 9.13 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 291 |
| Average Volume | 222 |
| Open | 116.60 |
| Previous Close | 115.25 |
| Day's Range | 116.55 - 117.45 |
| 52-Week Range | 99.00 - 186.85 |
| Beta | 0.13 |
| RSI | 60.18 |
| Earnings Date | Jul 31, 2025 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r... [Read more]
Financial Performance
In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.
Financial numbers in USD Financial StatementsNews
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Biogen (BIIB) To Contact Him Directly To Discuss Their Options
How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment
Biogen Inc. (NASDAQ: BIIB) CEO Chris Viehbacher said a successful Alzheimer’s trial for Novo Nordisk A/S’ (NYSE: NVO) weight-loss drug wouldn’t threaten his company’s treatment but could instead ope...
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period –
Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with ...
Biogen: Strong Q2 Doesn't Change The Math On Eroding MS Portfolio
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Biogen raises 2025 EPS guidance to $15.50-$16 as new launches drive 7% revenue growth
Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript
Biogen Inc. 2025 Q2 - Results - Earnings Call Presentation
BIIB Earnings: Highlights of Biogen’s Q2 2025 results
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) on Thursday reported higher revenues and adjusted profit for the second quarter of 2025. The company also raised its FY25 guidance to reflect a […] The po...
Earnings Snapshot: Biogen tops Q2 estimates, raises FY EPS outlook
Biogen reports Q2 results
Biogen rises as Alzheimer’s therapy drives Q2 beat
Biogen raises annual profit forecast on strong demand for rare disease drugs
Biogen raised its annual profit forecast on Thursday, betting on strong demand for its rare disease drugs such as Skyclarys to offset declining sales of its older multiple sclerosis drugs.
Biogen's Earnings Outlook
Biogen (NASDAQ: BIIB) is gearing up to announce its quarterly earnings on Thursday, 2025-07-31. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...
Biogen Q2 2025 Earnings Preview
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd.
Eisai/Biogen, Eli Lilly highlight long-term data backing Alzheimer’s drugs
Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds
Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years into treatment, according to new data presented at a medical meeting on Wedne...
KalVista, Biogen, Ionis get EU positive opinions for key drugs
ZURZUVAE (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a posi...
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a posi...
Biogen Inc (BIIB) Announces Key Presentations at 2025 Alzheimer's Association International ...
Biogen Inc (BIIB) Announces Key Presentations at 2025 Alzheimer's Association International Conference | BIIB stock news
Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer's Association International Conference (AAIC), ta...